BR112023023154A2 - Derivados espiro substituídos - Google Patents

Derivados espiro substituídos

Info

Publication number
BR112023023154A2
BR112023023154A2 BR112023023154A BR112023023154A BR112023023154A2 BR 112023023154 A2 BR112023023154 A2 BR 112023023154A2 BR 112023023154 A BR112023023154 A BR 112023023154A BR 112023023154 A BR112023023154 A BR 112023023154A BR 112023023154 A2 BR112023023154 A2 BR 112023023154A2
Authority
BR
Brazil
Prior art keywords
replaced
spiro derivatives
useful
derivatives
protein
Prior art date
Application number
BR112023023154A
Other languages
English (en)
Inventor
Sven Kramer Carsten
France Solange COLOMBEL Hélène
Noëlle Constance Pilatte Isabelle
Jianping Wu
Wilhelmus J Thuring Johannes
Lianzhu Liu
Lichao Fang
Luoheng Qin
Ming Li
Alexis Georges Querolle Olivier
René Angibaud Patrick
Vineet Pande
Sophie Poncelet Virginie
Wei Cai
Xuedong Dai
Yanping Xu
Yingtao Liu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR112023023154A2 publication Critical patent/BR112023023154A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Abstract

derivados espiro substituídos. a presente invenção se refere a agentes farmacêuticos úteis para terapia e/ou profilaxia em um mamífero, composição farmacêutica compreendendo tais compostos e seu uso como inibidores da interação menina/proteína mll/proteína, úteis para o tratamento de doenças como câncer, síndrome mielodisplásica (smd) e diabetes.
BR112023023154A 2021-05-08 2022-05-06 Derivados espiro substituídos BR112023023154A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2021092256 2021-05-08
PCT/CN2022/091065 WO2022237626A1 (en) 2021-05-08 2022-05-06 Substituted spiro derivatives

Publications (1)

Publication Number Publication Date
BR112023023154A2 true BR112023023154A2 (pt) 2024-01-23

Family

ID=76159225

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023154A BR112023023154A2 (pt) 2021-05-08 2022-05-06 Derivados espiro substituídos

Country Status (8)

Country Link
EP (1) EP4334310A1 (pt)
JP (1) JP2024518434A (pt)
KR (1) KR20240006542A (pt)
CN (1) CN117321049A (pt)
AU (1) AU2022272692A1 (pt)
BR (1) BR112023023154A2 (pt)
CA (1) CA3215379A1 (pt)
WO (1) WO2022237626A1 (pt)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473054B1 (en) 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
US9505781B2 (en) 2013-03-13 2016-11-29 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
US10588907B2 (en) 2015-06-04 2020-03-17 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
JP2018538330A (ja) 2015-12-22 2018-12-27 ヴァイティー ファーマシューティカルズ，インコーポレイテッド ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤
EP4219449A3 (en) 2016-03-16 2023-10-11 Kura Oncology, Inc. Substituted indole derivatives and methods of preparation thereof
CN109640987B (zh) 2016-03-16 2022-12-02 库拉肿瘤学公司 Menin-mll的桥联双环抑制剂及使用方法
CN109415337B (zh) 2016-05-02 2022-01-18 密执安大学评议会 作为多发性内分泌腺瘤蛋白抑制剂的哌啶
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
CA3024180A1 (en) 2016-06-10 2017-12-14 Vitae Pharmaceuticals, Inc. Inhibitors of the menin-mll interaction
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
BR112019004764A2 (pt) 2016-09-14 2019-05-28 Janssen Pharmaceutica Nv inibidores bicíclicos fundidos da interação menina-mll
ES2948949T3 (es) 2016-09-16 2023-09-22 Vitae Pharmaceuticals Llc Inhibidores de la interacción menina-MLL
EA201990699A1 (ru) 2016-10-05 2019-09-30 Янссен Фармацевтика Нв Спиробициклические ингибиторы взаимодействия менин–mll
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
US11944627B2 (en) 2017-03-24 2024-04-02 Kura Oncology, Inc. Methods for treating hematological malignancies and Ewing's sarcoma
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019060365A1 (en) 2017-09-20 2019-03-28 Kura Oncology, Inc. SUBSTITUTED MÉNINE-MLL INHIBITORS AND METHODS OF USE
MX2020006594A (es) 2017-12-20 2020-09-09 Janssen Pharmaceutica Nv Inhibidores de exo-azaespiro de la interaccion menina-mll.
EA202190623A1 (ru) 2018-08-27 2021-05-21 Сумитомо Дайниппон Фарма Ко., Лтд. Оптически активное азабициклическое производное
WO2020069027A1 (en) 2018-09-26 2020-04-02 Kura Oncology, Inc. Treatment of hematological malignancies with inhibitors of menin
CA3161045A1 (en) 2019-12-19 2021-06-24 Wei Cai Substituted straight chain spiro derivatives
CN111297863B (zh) 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用

Also Published As

Publication number Publication date
KR20240006542A (ko) 2024-01-15
CA3215379A1 (en) 2022-11-17
WO2022237626A1 (en) 2022-11-17
CN117321049A (zh) 2023-12-29
JP2024518434A (ja) 2024-05-01
EP4334310A1 (en) 2024-03-13
AU2022272692A1 (en) 2024-01-04

Similar Documents

Publication Publication Date Title
BR112019004764A2 (pt) inibidores bicíclicos fundidos da interação menina-mll
BR112019004691A2 (pt) inibidores bicíclicos em espiro da interação menina-mll
JOP20220154A1 (ar) مشتقات سبيرو بسلسلة مستقيمة بها استبدال
EA201990699A1 (ru) Спиробициклические ингибиторы взаимодействия менин–mll
CR11201A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas
CR11200A (es) Derivados de morfolino pirimidina utilizados en enfermedades relacionadas con mtor quinasa y/o p13k
BRPI0714803B8 (pt) compostos peptidomiméticos de smac, seus usos, e composição farmacêutica
BR112022000251A2 (pt) Derivados macrocíclicos de espirociclo como inibidores de mcl-1
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
BR112023000212A2 (pt) Éter macrocíclico contendo derivados de indol como inibidores de mcl-1
BR112017007708A2 (pt) composto macrocíclicos, uso de um composto macrocíclicos, método para tratamento, unidade de dose, composição farmacêutica e método para tratar câncer em um paciente
BR112021025732A2 (pt) Inibidores macrocíclicos de mcl-1
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
BR112023023463A2 (pt) Inibidores da interação menin-mll
CO2023016217A2 (es) Derivados de fenil-1h-pirrolo[2,3-c]piridina sustituidos
BR112023023154A2 (pt) Derivados espiro substituídos
BR112023021040A2 (pt) Derivados espiro substituídos
BR112022009142A2 (pt) Derivados de indol macrocíclicos como inibidores de mcl-1
BR112022009754A2 (pt) Derivados macrocíclicos de sulfonila como inibidores de mcl-1
BR112019012106A2 (pt) inibidores de azepano de interação menin-mill
BR112022024117A2 (pt) Derivados de 7-pirazol-5-il-indol macrocíclico como inibidores de mcl-1
BR112023025436A2 (pt) Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
BR112022025631A2 (pt) Derivados de 4-(pirazol-5-il)-indol macrocíclico n-ligados como inibidores de mcl-1
BR112023020877A2 (pt) 2-aliltetra-hidrofuranos macrocíclicos como inibidores de mcl-1